Modern Architect · 1963 — Present

Robert Bradway

Architect of Amgen's global expansion and portfolio diversification in a challenging biotech landscape.

Country

United States

Continent

North America

Industry

Biotechnology

Role

CEO, Amgen

Robert A. Bradway has served as Chairman and Chief Executive Officer of Amgen since 2012. He joined Amgen in 2006 as Vice President, Operations Strategy. Bradway's tenure at Amgen has been characterized by significant strategic acquisitions, global market expansion, and an emphasis on navigating the evolving biopharmaceutical pricing and regulatory environment, transforming Amgen from a mature biotechnology company into a diversified global leader.

Biography

Robert A. Bradway, born in 1963, assumed the role of CEO of Amgen Inc. in May 2012, and became Chairman of the Board in December 2012. Prior to his CEO appointment, Bradway served as President and Chief Operating Officer from 2010 to 2012, and before that as Executive Vice President and Chief Financial Officer from 2007 to 2010. He initially joined Amgen in 2006 as Vice President, Operations Strategy. Before Amgen, Bradway was a Managing Director at Morgan Stanley in London, where he was responsible for the firm's healthcare investment banking activities in Europe. His extensive background in finance and strategic transactions has heavily influenced Amgen's corporate development strategy under his leadership. Under Bradway, Amgen has focused on maximizing the value of its established product portfolio while investing heavily in biosimilars, oncology, and inflammatory disease franchises. Notable strategic moves include the 2013 acquisition of Onyx Pharmaceuticals for approximately $10.4 billion, which added the multiple myeloma drug Kyprolis to Amgen's oncology pipeline. He has also championed global expansion, particularly into emerging markets, and overseen significant investment in Amgen's manufacturing and R&D capabilities. Bradway has navigated periods of patent expirations for key products like Neupogen and Epogen by emphasizing pipeline innovation and market diversification, including a substantial push into the biosimilars market.

Accomplishments

01Orchestrated the acquisition of Onyx Pharmaceuticals for approximately $10.4 billion in 2013, significantly expanding Amgen's oncology portfolio with Kyprolis.
02Spearheaded Amgen's entry and expansion into the biosimilars market, generating a new revenue stream to offset biosimilar competition for Amgen's own products.
03Navigated Amgen through the patent expirations of blockbuster drugs like Neupogen and Epogen, maintaining revenue stability through pipeline development and strategic diversification.
04Drove significant global expansion, particularly into emerging markets, establishing Amgen's presence in key international territories.
05Oversaw the development and launch of key innovative therapies, including Repatha (cholesterol) and Aimovig (migraine), diversifying Amgen's therapeutic areas.
06Initiated the acquisition of Five Prime Therapeutics for $1.9 billion in 2021, adding bemarituzumab for gastric cancer to the pipeline, and ChemoCentryx for $3.7 billion in 2022, securing Tavneos for ANCA-associated vasculitis.

Lessons for Operators

Proactive Diversification Against Patent Cliffs: Bradway demonstrated the imperative to diversify revenue streams, specifically through biosimilar development and strategic acquisitions, well in advance of anticipated patent expirations to mitigate revenue decline.

Strategic M&A for Portfolio Enhancement: Evaluate acquisition targets not merely for immediate revenue but for their strategic fit, pipeline synergy, and long-term market potential, as seen with Onyx Pharmaceuticals.

Global Market Penetration as a Growth Lever: Even for established companies, significant growth can be found by methodically expanding into under-addressed international markets, tailoring strategies to local regulatory and commercial environments.

Innovation as a Continuous Process: Sustained R&D investment and a willingness to explore new therapeutic areas are critical to remaining competitive and replacing revenue from maturing assets.

Agility in Biosimilar Strategy: Develop an offensive and defensive strategy for biosimilars – both developing biosimilars to compete and defending against them by emphasizing the value proposition of branded biologics.

The Operator's Playbook

Key Takeaways

Practical lessons distilled for operators, investors, C-levels, and capital allocators.

Lesson 01

Mitigating Patent Cliff Impact

Bradway's tenure exemplifies a multi-pronged strategy to manage the impact of patent expirations: invest in new R&D, pursue strategic acquisitions for pipeline diversification, and actively enter the biosimilar market. This proactive approach ensures long-term revenue stability.

Lesson 02

The Dual Role of Biosimilars

Under Bradway, Amgen not only faced biosimilar competition but also became a significant biosimilar provider. This demonstrates that a robust biosimilar strategy involves both protecting proprietary assets and leveraging manufacturing and commercial capabilities to compete in the generic biologics space.

Lesson 03

Strategic Acquisition for Therapeutic Expansion

The Onyx Pharmaceuticals acquisition was not just about revenue; it was about expanding Amgen's oncology footprint and adding a high-value asset (Kyprolis) to its pipeline. This illustrates that M&A should align with and accelerate core therapeutic area strategies.

Lesson 04

Global Reach, Local Depth

Bradway prioritized international expansion. Companies seeking global growth must not just enter new markets but invest in understanding local regulatory, commercial, and healthcare system nuances to achieve sustainable success.

Lesson 05

Balancing Legacy and Innovation

Amgen under Bradway successfully balanced maximizing value from its mature, highly successful products while consistently investing in novel drug discovery and development. This dual focus is crucial for sustained leadership in a fast-evolving industry.

Mental Models

Frameworks & Principles

Named frameworks and strategic principles they popularized or embodied.

Portfolio Lifecycle Management (Amgen Adaptation)

A refined approach where products are managed through discovery, development, launch, maturity, and patent expiration, with specific strategies at each stage including preemptive R&D, targeted acquisitions, and biosimilar development/defense to smooth revenue curves.

When to useApplicable for any enterprise reliant on intellectual property and facing product obsolescence risks, particularly in pharmaceuticals, technology, or advanced manufacturing, to ensure continuous revenue streams.

Global Market Penetration & Localization

A strategy emphasizing methodical entry into international markets, leveraging existing infrastructure where possible, but critically adapting commercial and regulatory strategies to local requirements, understanding cultural nuances and healthcare systems.

When to useEssential for companies seeking to expand beyond domestic markets, especially in industries with complex regulatory environments, diverse healthcare funding models, or significant cultural variations like pharmaceuticals or consumer goods.

Strategic M&A for Capability vs. Competitor Elimination

A framework for evaluating acquisitions primarily based on their ability to enhance internal capabilities, add specialized pipelines, or provide market access in new therapeutic areas, rather than solely eliminating competitive threats or market share consolidation.

When to useSuitable for companies looking to organically grow through inorganic means, particularly when seeking to diversify into new product areas, acquire specific technological capabilities, or accelerate pipeline development in highly competitive sectors.

Adjacent Minds